<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: AstraZeneca shares dip despite Chinese marketing approval	</title>
	<atom:link href="https://ukinvestormagazine.co.uk/astrazeneca-shares-dip-despite-chinese-marketing-approval/feed/" rel="self" type="application/rss+xml" />
	<link>https://ukinvestormagazine.co.uk/astrazeneca-shares-dip-despite-chinese-marketing-approval/</link>
	<description>UK Investor Magazine provides breaking financial news and investment ideas</description>
	<lastBuildDate>Tue, 21 Jan 2020 15:36:00 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.5</generator>
	<item>
		<title>
		By: GSK shares receive boost on US drug applicaton - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/astrazeneca-shares-dip-despite-chinese-marketing-approval/#comment-13802</link>

		<dc:creator><![CDATA[GSK shares receive boost on US drug applicaton - UK Investor Magazine]]></dc:creator>
		<pubDate>Tue, 21 Jan 2020 15:36:00 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=24812#comment-13802</guid>

					<description><![CDATA[[&#8230;] industry working with firms such as AstraZeneca (LON: AZN) &#8211; who notably updated the market this morning about the approval of a Chinese marketing [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] industry working with firms such as AstraZeneca (LON: AZN) &#8211; who notably updated the market this morning about the approval of a Chinese marketing [&#8230;]</p>
]]></content:encoded>
		
			</item>
		<item>
		<title>
		By: Shield Therapeutics get green light for Feraccru/Accrufer in China - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/astrazeneca-shares-dip-despite-chinese-marketing-approval/#comment-13509</link>

		<dc:creator><![CDATA[Shield Therapeutics get green light for Feraccru/Accrufer in China - UK Investor Magazine]]></dc:creator>
		<pubDate>Wed, 08 Jan 2020 12:23:49 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=24812#comment-13509</guid>

					<description><![CDATA[[&#8230;] AstraZeneca (LON:AZN) updated the market by saying that it had won approval in China for its Roxadust [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] AstraZeneca (LON:AZN) updated the market by saying that it had won approval in China for its Roxadust [&#8230;]</p>
]]></content:encoded>
		
			</item>
		<item>
		<title>
		By: Deepmatter shares surge on AstraZeneca partnership - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/astrazeneca-shares-dip-despite-chinese-marketing-approval/#comment-13076</link>

		<dc:creator><![CDATA[Deepmatter shares surge on AstraZeneca partnership - UK Investor Magazine]]></dc:creator>
		<pubDate>Mon, 09 Dec 2019 11:21:59 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=24812#comment-13076</guid>

					<description><![CDATA[[&#8230;] is a FTSE100 (INDEXFTSE: UKX) and announced that it had received received marketing authorization from China’s National Medical Products Administration for their Lynparza drug with partner Merck [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] is a FTSE100 (INDEXFTSE: UKX) and announced that it had received received marketing authorization from China’s National Medical Products Administration for their Lynparza drug with partner Merck [&#8230;]</p>
]]></content:encoded>
		
			</item>
		<item>
		<title>
		By: China says tariffs must be rolled back for a deal to be done - UK Investor Magazine		</title>
		<link>https://ukinvestormagazine.co.uk/astrazeneca-shares-dip-despite-chinese-marketing-approval/#comment-13051</link>

		<dc:creator><![CDATA[China says tariffs must be rolled back for a deal to be done - UK Investor Magazine]]></dc:creator>
		<pubDate>Thu, 05 Dec 2019 16:30:35 +0000</pubDate>
		<guid isPermaLink="false">https://ukinvestormagazine.co.uk/?p=24812#comment-13051</guid>

					<description><![CDATA[[&#8230;] PLC (LON: GLEN) being investigated by the SFO, AJ Bell PLC (LON: AJB) posting a strong full-year, AstraZeneca plc (LON: AZN) receiving Chinese authorisation and Bigblu Broadband plc (AIM: BBB.L) suffering due to [&#8230;]]]></description>
			<content:encoded><![CDATA[<p>[&#8230;] PLC (LON: GLEN) being investigated by the SFO, AJ Bell PLC (LON: AJB) posting a strong full-year, AstraZeneca plc (LON: AZN) receiving Chinese authorisation and Bigblu Broadband plc (AIM: BBB.L) suffering due to [&#8230;]</p>
]]></content:encoded>
		
			</item>
	</channel>
</rss>
